Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey

BACKGROUND/AIM: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. MATERIALS AND METHODS: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. RESULTS: The median age at ruxolitinib initiation was 62 (28–87) a...

Descripción completa

Detalles Bibliográficos
Autores principales: SOYER, Nur, ALİ, Rıdvan, TURGUT, Mehmet, C. HAZNEDAROĞLU, İbrahim, YILMAZ, Fergün, AYDOĞDU, İsmet, PİR, Ali, KARAKUŞ, Volkan, ÖZGÜR, Gökhan, KİS, Cem, CERAN, Funda, İLHAN, Gül, ÖZKAN, Melda, ASLANER, Müzeyyen, İNCE, İdris, YAVAŞOĞLU, İrfan, GEDİZ, Füsun, SÖNMEZ, Mehmet, GÜVENÇ, Birol, ÖZET, Gülsüm, KAYA, Emin, VURAL, Filiz, ŞAHİN, Fahri, TÖBÜ, Mahmut, DURUSOY, Raika, SAYDAM, Güray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283435/
https://www.ncbi.nlm.nih.gov/pubmed/33315343
http://dx.doi.org/10.3906/sag-1812-70

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283435/
https://www.ncbi.nlm.nih.gov/pubmed/33315343
http://dx.doi.org/10.3906/sag-1812-70

Ejemplares similares